AN-018

AN-018 is a preclinical-stage small molecule therapeutic developed by Accuitis, Inc. designed to treat neurodegenerative and neurocognitive disorders. It acts as a restorer of mitochondrial **Sirtuin 3 (SIRT3)** expression and signaling, which is critical for maintaining healthy mitochondrial metabolism and cellular stress resistance. In preclinical models of Alzheimer's Disease, AN-018 has demonstrated the ability to activate SIRT3 signaling in the hippocampus and cerebral cortex while inhibiting **Glycogen synthase kinase-3 beta (GSK-3β)** activity, thereby addressing tau hyperphosphorylation. The compound has further shown neuroprotective efficacy in models of Parkinson's Disease, HIV-Associated Neurocognitive Disorder (HAND), and methamphetamine addiction, where it has been observed to reverse cognitive abnormalities, reduce astrogliosis, and inhibit the activation of mononuclear phagocytes.